To view this email as a web page, click here.
 
First-in-class targeted drug approved for acute myeloid leukemia
Ivosidenib (Tibsovo) is the first drug approved for acute myeloid leukemia patients with a specific genetic mutation.
How it’s unique
ADVERTISEMENT
 
Breast cancer drug first to get nod in FDA accelerated approval program
A breast cancer drug is the first approval from FDA in 2 new pilot programs that make the development and review of cancer drugs more efficient.
Read more
 
Cancer in the news: 3 stories you can’t miss
A pharma maker is under fire for raising prices on its cancer drugs. Meanwhile, there were two major cancer drug approvals in June. Here are the top 3 cancer news articles in the past month.
Read more
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.